Caidya
Caidya is a clinical research organization (CRO) that combines scientific, medical, and operational expertise to drive complex clinical development and cross-border trials.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Caidya is a CRO that provides clinical development services, with expertise in oncology, hematology, and rare disease. The company emphasizes agility, global reach, and patient-centric solutions. It was formed through the merger of dMed and Clinipace in 2021 and rebranded as Caidya in 2022. In 2025, it received a strategic growth investment from Rubicon Founders, and in 2026 it combined with Simbec-Orion.
History
Caidya was formed through the merger of dMed and Clinipace in 2021, and rebranded as Caidya in 2022. In 2024, Barbara Lopez Kunz was named CEO. In 2025, Caidya received a strategic growth investment of $165M from Rubicon Founders. In 2026, Caidya combined with Simbec-Orion.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/caidya · Editorial policy · How profiles are compiled